Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape

Source: Navigating the Complex Treatment Landscape in Relapsed/Refractory Myeloma
Listen as experts answer common questions on current therapeutic options for patients with relapsed/refractory multiple myeloma.
Natalie S. Callander, MD
Noopur Raje, MD
Paul G. Richardson, MD
Released: October 24, 2022

In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include:

  • How to sequence currently available therapies after relapse
  • Challenges with using BCMA-targeted agents in clinical practice
  • Experts’ thoughts on the potential approval of bispecific agents

Information on this Educational Activity

Faculty

Paul G. Richardson, MD

R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD: consultant/advisor/speaker: AstraZeneca, Celgene/Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio, Takeda; researcher: Celgene/Bristol-Myers Squibb, Karyopharm, Oncopeptides, Takeda.
Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has no relevant financial relationships to disclose.
Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor/speaker: Amgen, AbbVie, Bristol-Myers Squibb, Caribou Biosciences & Immuneel, Janssen, Pfizer, Sanofi, Takeda; researcher: Bluebird Bio.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics Inc.
Regeneron Pharmaceuticals, Inc.

Related Content

On-demand webcast from an ASH 2022 satellite symposium on new and emerging agents for myelodysplastic syndromes, from Clinical Care Options (CCO)

María Díez Campelo, MD, PhD Rami Komrokji, MD Amer Zeidan, MBBS, MPH Physicians: maximum of 2.0 AMA PRA Category 1 Credits™ Released: January 27, 2023 Expired: January 26, 2024

Downloadable slideset from a text module on systemic therapies for advanced hepatocellular carcinoma, from Clinical Care Options (CCO)

Stacey Stein, MD Released: January 27, 2023

Dr Eric Jonasch discusses advances in the care of patients with renal cell carcinoma in this on-demand webcast from Clinical Care Options (CCO)

Naomi B. Haas, MD
Program Director Eric Jonasch, MD
Program Director Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: January 26, 2023 Expired: January 25, 2024

SWOG 1815 trial evaluating the first-line nab-paclitaxel + gemcitabine/cisplatin in advanced biliary tract cancers, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 26, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings